Premium
Current landscape for treatment of advanced basal cell carcinoma
Author(s) -
Foley Peter
Publication year - 2015
Publication title -
australasian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.67
H-Index - 53
eISSN - 1440-0960
pISSN - 0004-8380
DOI - 10.1111/ajd.12319
Subject(s) - vismodegib , basal cell carcinoma , medicine , hedgehog signaling pathway , skin cancer , basal cell nevus syndrome , melanoma , incidence (geometry) , cancer , dermatology , basal cell , oncology , cancer research , signal transduction , biochemistry , chemistry , physics , optics
Basal cell carcinomas ( BCCs ) account for around 80% of non‐melanoma skin cancer. A ustralia has the highest incidence of BCC globally and the rates continue to increase in both A ustralia and N ew Z ealand. BCC causes significant morbidity, placing an enormous burden on the healthcare system. Treatment of patients with advanced BCC can be particularly challenging. A panel of UK experts recently defined advanced disease as BCC that in which current treatment modalities are considered potentially contraindicated by clinical or patient‐driven factors. Research has found that mutations in the hedgehog signalling pathway underpin the pathogenesis of the vast majority of sporadic BCC , as well as Gorlin syndrome. The first‐in‐class oral small molecule hedgehog pathway inhibitor – vismodegib–is now approved in a number of countries for use in locally‐advanced and metastatic BCC and has resulted in improved outcomes in the majority of patients treated. With a number of similar agents in the pipeline, research is now focusing on identifying mechanisms that may contribute to resistance to this agent in some lesions.